Cancer Cell Signaling Prgm

癌细胞信号转导方案

• 批准号: 9365066
• 负责人: GORDON D GINDER
• 金额: $ 7.69万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-05-01 至 2017-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9365066
• 关键词: Affect; Bioenergetics; Cancer Center; Cancer Center Support Grant; Cell Survival; Cellular biology; Clinical; Collaborations; Development; Direct Costs; Environment; Event; Fostering; Funding; Funding Agency; Genes; Genetic Programming; Goals; Grant; Humanities; Inflammation; Instruction; Laboratory Study; Lipids; Malignant Neoplasms; Molecular; Molecular Genetics; Peer Review; Phase I/II Trial; Publications; Research; Research Personnel; Role; Science; Signal Pathway; Signal Transduction; Transgenic Model; United States National Institutes of Health; Universities; Virginia; Xenograft Model; anticancer research; base; cancer cell; cell behavior; college; inhibitor/antagonist; interdisciplinary approach; interest; medical schools; meetings; multidisciplinary; neoplastic cell; pre-clinical; programs; success; therapeutic target; tumor; tumorigenesis

The Cancer Cell Signaling (CCS) program is a newly formed program resulting from the restructuring of the former Cancer Cell Biology program into two more cohesive programs [the other being the Cancer Molecular Genetics program (CMG)]. The CCS program consists of a multidisciplinary group of 18 investigators from 6 academic departments from the School of Medicine and the College of Humanities and Sciences, who share a common interest in elucidation of cellular and molecular signaling events governing neoplastic cell behavior and survival. They also share the overarching scientific goals of: 1) examining the role of bioactive lipids in tumor formation; 2) identifying key signaling pathways that are perturbed in cancer cells; 3) understanding the interactions among metabolites, inflammation, bioenergetics, genes, and the environment that affect tumorigenesis; and 4) identifying potential therapeutic targets and strategies based upon an understanding of cancer cell signaling and to develop a rational basis for combining inhibitors of these. The CCS program also has a strong pre-clinical thrust with investigators utilizing xenograft and transgenic models seeking to develop treatments involving agents that act by modulating various signal transduction networks. The CCS program has a funding base of roughly $6.8 million dollars in annual direct support, of which $6.25 is from NIH and other peer-reviewed funding sources. The funding base includes 9 funded projects from NCI with a total of $1.4 million in annual direct costs. CCS fosters the development of intra and inter-programmatic interactions by organizing seminars and regular meetings among the entire program membership, as well as focused discussion groups with overlapping research interests that have led to numerous co-publications and new collaborative grants. The success of this broad, interdisciplinary approach to cancer research is demonstrated by the track record of CCS program investigators with 260 publications since 2008 of which 15% represent intra-programmatic collaborations, 34% represent inter-programmatic collaborations, and 5% both intra and inter-programmatic collaborations, and in developing initiatives that have progressed from basic laboratory studies to 8 multi-institutional clinical Phase I/II trials with other Virginia Commonwealth University (VCU) Massey Cancer Center (MCC) programs.

癌细胞信号传导（CCS）程序是由重组的新成立的程序 以前的癌细胞生物学计划将两个凝聚力程序分为两个粘合剂[另一个是癌症分子 遗传学计划（CMG）]。 CCS计划由一个来自6个调查人员组成的多学科小组 分享医学院和人文与科学学院的学术系 阐明控制肿瘤细胞的细胞和分子信号事件的共同兴趣 行为和生存。他们还共享：1）检查生物活性的作用的总体科学目标 肿瘤形成中的脂质； 2）识别癌细胞扰动的关键信号通路； 3） 了解代谢物，炎症，生物能学，基因和环境之间的相互作用 影响肿瘤发生； 4）基于 了解癌细胞信号传导并开发合理的基础，以结合其抑制剂。这 CCS计划还具有强大的临床前推力，利用异种移植和转基因的研究人员 寻求开发涉及通过调节各种信号转导作用的药物的治疗的模型 网络。 CCS计划的资金基础约为680万美元的年度直接支持， 6.25美元来自NIH和其他同行评审的资金来源。资金基础包括9个资助 NCI的项目总收入为140万美元。 CCS促进了内部和 通过组织研讨会和整个计划中的定期会议来进行跨编程互动 会员资格以及集中讨论小组具有重叠的研究兴趣，这导致了 众多共同发布和新的合作赠款。这个广泛的跨学科的成功 CCS计划调查员的记录证明了癌症研究方法的方法260 自2008年以来的出版物，其中15％代表了截面的合作，34％代表策略间 合作，以及5％的内部和程序间合作，以及开发 从基础实验室研究发展到8个多机构临床I/II阶段试验的计划 与其他弗吉尼亚联邦大学（VCU）梅西癌症中心（MCC）计划。